Skip to main content
SpringerLink
Log in

Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

Hepatitis C virus genotype 4 (HCV-GT4) is a risk factor for cirrhosis, hepatocellular carcinoma and liver failure. A combination of three new direct-acting antivirals ombitasvir, paritaprevir, and ritonavir has been recommended for treatment of HCV-GT4 infection. The current study was aimed to assess the efficacy and safety of this combination plus ribavirin in non-cirrhotic, treatment-naïve and -experienced Egyptians with HCV-GT4 infection in a real-world setting. A total of 255 Egyptians with HCV-GT4 infection were enrolled, including 82 treatment-experienced and 173 treatment-naïve patients. All of them completed 12-week treatment protocol of ombitasvir, paritaprevir and ritonavir as an oral dose combination with ribavirin. Virological response (VR) was measured, as well as the biochemical parameters related to treatment efficacy and adverse events at baseline and after treatment, at 4 (VR4) and 12 (VR12) weeks post-treatment. The results showed that the VR4 rates were 98.8% in both groups, and VR12 rates were 97.7% and 96.3% in treatment-naïve and -experienced patients, respectively, with no significant differences found between the groups concerning VR4 (P=0.9) and VR12 (P=0.3). The most common adverse events were headache and fatigue, which were significantly more common (P=0.001 and 0.003, respectively) in treatment-experienced than in treatment-naïve group. The quadruple regimen was well-tolerated, and the reported adverse events were generally mild to moderate. This real-world setting study confirms that the combination of ombitasvir, paritaprevir, ritonavir, and ribavirin is highly effective in the treatment of HCV- GT4 infection with a good safety and tolerability profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int, 2017,37(1):45–53

    Article  CAS  Google Scholar 

  2. Gower E, Estes C, Black S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014,61(1 Suppl):S45–S57

    Article  Google Scholar 

  3. Wahsh EA, Hussein AK, Gomaa AA, et al. Real life Egyptian experience of daclatasvir plus sofosbuvir with Ribavirin in Naïve difficult to treat HCV patients. Infect Disord Drug Targets, 2020,20(1):43–48

    Article  CAS  Google Scholar 

  4. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017,66(1):153–194

    Article  Google Scholar 

  5. Ahmed H, Ahmed E, Abushouk AI, et al. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. Antivir Ther, 2017,22(5):369–379

    Article  CAS  Google Scholar 

  6. Ahmed H, Abushouk AI, Attia A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis. J Infect Public Heal, 2018,11(2):156–164

    Article  Google Scholar 

  7. Ahmed H, Abushouk AI, Menshawy A, et al. Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection. Ann Hepatol, 2018,17(1):18–32

    Article  Google Scholar 

  8. Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int, 2016,36(Suppl 1):47–57

    Article  Google Scholar 

  9. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int, 2011,31(Suppl 2):61–80

    Article  Google Scholar 

  10. Ray SC, Arthur RR, Carella A, et al. Genetic Epidemiology of Hepatitis C Virus throughout Egypt. J Infect Dis, 2000,182(3):698–707

    Article  CAS  Google Scholar 

  11. Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother, 2015,59(2):979–987

    Article  Google Scholar 

  12. Poordad F, Landis CS, Asatryan A, et al. High antiviral activity of NS 5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int, 2016,36(8):1125–1132

    Article  CAS  Google Scholar 

  13. Pockros P, Reddy R, Mantry P, et al. RUBY-I: ombitasvir/paritaprevir/ritonavir+ dasabuvir+/-ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease. Hepatology, 2015,62(Suppl 1):716A

    Google Scholar 

  14. Polepally AR, Badri PS, Eckert D, et al. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. Eur J Drug Metab Pharmacokinet, 2017,42(2):333–339

    Article  CAS  Google Scholar 

  15. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology, 2016,151(1):70–86

    Article  CAS  Google Scholar 

  16. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol, 2016,2(2):34–37

    Article  Google Scholar 

  17. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet, 2015,385(9986):2502–2509

    Article  Google Scholar 

  18. Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol, 2016,1(1):36–44

    Article  Google Scholar 

  19. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006,43(6):1317–1325

    Article  CAS  Google Scholar 

  20. Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol, 2016,22(35):8050–8059

    Article  CAS  Google Scholar 

  21. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 2016,151(3):457–471

    Article  CAS  Google Scholar 

  22. Ahmed H, Abushouk AI, Menshawy A, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig, 2017,37(11):1009–1023

    Article  Google Scholar 

  23. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology, 2014,59(1):318–327

    Article  Google Scholar 

  24. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol, 2015,63(3):581–585

    Article  CAS  Google Scholar 

  25. Manns M, Gane EJ, Willems BE, et al. The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis. J Hepatol, 2017,66(Suppl 1):S722–S723

    Article  Google Scholar 

  26. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology, 2016,64(4):1049–1056

    Article  CAS  Google Scholar 

  27. Said EM, Abdulaziz BA, El Kassas M, et al. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir+ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol, 2020,165:1633–1639

    Article  CAS  Google Scholar 

  28. Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci, 2018,63(5):1341–1347

    Article  CAS  Google Scholar 

  29. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology, 2014,147(2):359–365

    Article  CAS  Google Scholar 

  30. Stauber RE, Fauler G, Rainer F, et al. Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus. Wiener klinische Wochenschrift, 2017,129(21):848–851

    Article  CAS  Google Scholar 

  31. McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther, 2006,318(3):1068–1075

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Beni Suef University, Beni Suef, 62521, Egypt

    Manar Ahmed & Hoda M. Rabea

  2. Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Al Menoufia, 32511, Egypt

    Azza E. Mansey

  3. Department of Clinical Pharmacy, Faculty of Pharmacy, October 6 university, Giza, 12573, Egypt

    Engy A. Wahsh

  4. Department of Tropical Medicine, Faculty of Medicine, Fayoum University, Fayoum, 63511, Egypt

    Ahmed A. Gomaa

Authors
  1. Manar Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azza E. Mansey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Engy A. Wahsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed A. Gomaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hoda M. Rabea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Engy A. Wahsh.

Ethics declarations

The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, M., Mansey, A.E., Wahsh, E.A. et al. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. CURR MED SCI 41, 581–586 (2021). https://doi.org/10.1007/s11596-021-2363-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-021-2363-9

Key words

Search

Navigation